Full-Time

Labeling Group Lead

Global Regulatory Affairs

Deadline 9/30/26
Sanofi

Sanofi

10,001+ employees

Global pharma company; vaccines and R&D

No salary listed

Hyderabad, Telangana, India

Hybrid

Hybrid work in Hyderabad.

Bachelor's, Master's

Category
Biology & Biotech (1)
Required Skills
Data Visualization

Get referred to Sanofi

See people who can refer or advise you

Requirements
  • Knowledge of regulatory and labeling requirements in major markets for marketing authorization filings for new products or updates to marketed products.
  • Extensive knowledge of drug labeling requirements, including CCDS, European Union and United States guidance and regulations, and drug-device combinations.
  • Ability to lead labeling strategy and connect it to regulatory strategy.
  • Ability to lead matrix teams, manage up, negotiate, and build consensus on complex topics.
  • Ability to lead multidisciplinary labeling working groups involving Global Regulatory Affairs, Global Pharmacovigilance, Global Medical Affairs, Legal, preclinical, and CMC functions.
  • Deep knowledge of end-to-end labeling processes and interfaces between Regulatory, Medical Affairs, Pharmacovigilance, Quality, and Supply Chain.
  • At least 15 years of relevant regulatory and labeling experience.
  • At least 5 years of people management, team management, and project management experience.
  • Ability to recruit, hire, and onboard staff, including defining role competencies and evaluating candidates.
  • Experience building and executing training plans, assessing competency, and closing individual training gaps through targeted development.
  • Experience conducting performance management through goal setting, feedback, and coaching for a team.
  • Ability to assign and balance product responsibility across a team based on capacity and skill level.
  • Experience managing resource planning and coverage across vacations, turnover, sick leave, and peak workloads without disrupting deliverables.
  • Ability to forecast capacity against portfolio demand and reallocate work when gaps emerge.
  • Experience developing contingency and backup coverage models so no product goes unowned.
  • Experience establishing and monitoring quality and timeliness KPIs and metrics.
  • Working knowledge of project and portfolio management methods for competing deadlines across a large product portfolio.
  • Ability to work with associates and management at all company levels, domestically and internationally.
  • Ability to support global discussions and local countries as a global labeling subject matter expert.
  • Ability to construct and guide creation of company responses to European Union and United States health authority questions related to labeling.
  • Ability to build or learn scientific knowledge, such as statistics and disease-area knowledge, to work across therapeutic areas.
  • Familiarity with labeling and document management systems, including Veeva Vault, EDMS, RIM systems, and text verification or quality-control tools.
  • Ability to search public data on labeling elements and regulatory strategy.
  • Demonstrated ability to track and report portfolio status using dashboards, trackers, or portfolio management tools.
  • Physician, Pharmacist, Veterinarian, or Life Sciences degree.
  • Fluent business English.
Responsibilities
  • Recruit, hire, and onboard team members, including defining role competencies and evaluating candidates.
  • Build and execute training plans, assess team-member competency, and close individual training gaps through targeted development.
  • Conduct performance management through goal setting, feedback, and coaching for a team.
  • Assign and balance product responsibility across a team based on capacity and skill level.
  • Manage resource planning and coverage across vacations, turnover, sick leave, and peak workloads without disrupting deliverables.
  • Ensure coverage for products and projects within the group by identifying gaps and resource constraints and implementing solutions for management consideration.
  • Forecast capacity against portfolio demand and reallocate work when gaps emerge.
  • Develop contingency and backup coverage models so no product goes unowned.
  • Track and report status across a large portfolio using dashboards, trackers, or portfolio management tools.
  • Establish and monitor KPIs and metrics for labeling quality and timeliness, including on-time submission rate, error or deviation rate, and cycle time.
  • Use project and portfolio management methods to manage competing deadlines across 250 products.
  • Lead labeling strategists in creating or updating corporate labeling documents and corresponding patient leaflets for development, lifecycle-management, and marketed products.
  • Coordinate and ensure accountability throughout the end-to-end labeling review and approval process.
  • Prepare labeling components for submission to regulatory agencies and participate in labeling negotiations that result in product approvals or updates.
  • Ensure the team supports cross-functional groups as a labeling expert and contributes to global regulatory strategies and submission dossiers or health-authority responses.
  • Chair multidisciplinary labeling working groups, present labeling proposals, and develop consensus for presentation to the Labeling Governance Committee.
  • Provide oversight and guidance for the team and assigned products, including strategic guidance and training for complex labeling projects.
  • Serve as a representative of the extended Global Regulatory Affairs Labeling Leadership team.
  • Participate in response teams for highly complex European Union and United States procedures, including arbitration, referrals, work sharing, PRAC questions, signal detection, labeling negotiations, and urgent safety restrictions.
  • Identify portfolio risks and implementation hurdles and act to minimize them while informing management as needed.
  • Coordinate, create, and clearly present labeling proposals to Senior Executive Management through the Labeling Review Committee.
  • Guide assessment of relevant study reports, post-marketing pharmacovigilance data, and other scientific reports supporting labeling proposals.
  • Direct complex labeling competitive and comparator analyses to provide expert-level insights.
  • Meet established submission timelines and quality standards for labeling deliverables.
  • Provide training and mentoring to junior labeling team members on CCDS, European Union and United States guidance and regulations, and their implementation in labeling text.
  • Lead complex transversal or process-improvement workstreams across labeling and Global Regulatory Affairs topics.
  • Interpret and apply health-authority requirements from the Food and Drug Administration, European Medicines Agency, and other relevant agencies.
Desired Qualifications
  • An advanced degree.

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 sales rose 13.6%, while launches grew 49.6% and Dupixent 30.8%.
  • July 2026 FDA approval expanded Sarclisa across all U.S. myeloma indications.
  • Paulo Fontoura assumed R&D leadership on September 1, 2026, accelerating pipeline execution.

What critics are saying

  • Tolebrutinib’s FDA rejection on December 24, 2025 exposed severe liver-injury risk.
  • Dupixent lawsuits consolidated in New Jersey by June 2026 threaten label and damages exposure.
  • Sanofi’s insulin plant needed €400 million German aid on September 8, 2026, signaling supply fragility.

What makes Sanofi unique

  • Dupixent posted €4.17 billion Q1 2026 sales, dominating immunology globally.
  • Sanofi’s July 2026 Sarclisa Escena became the first cancer on-body injector treatment.
  • Sanofi secured Cenrifki EU approval in June 2026, advancing a differentiated MS franchise.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

La Croix
Sep 8th, 2026
EU approves $448M German subsidy to Sanofi for insulin production security

The European Commission has approved a €400 million subsidy from Germany to pharmaceutical company Sanofi to maintain its Frankfurt insulin production site. The Commission stated that without this aid, Sanofi would close the German facility, reducing insulin supply security across the European Economic Area. The subsidy aims to compensate Sanofi for costs related to a service of general economic interest, strengthening insulin supply resilience for German patients. In return, Sanofi must build a new insulin factory in Frankfurt by 31 December 2032 and guarantee minimum annual production of 1.1 tonnes until 2042. Sanofi is among the world's leading insulin producers. The company announced in 2024 a €1.3 billion investment in Frankfurt to construct a new complex replacing existing facilities.

StreetInsider
Aug 25th, 2026
Altesa BioSciences wins award for oversubscribed $75M Series B to advance COPD therapies

Atlanta-based Altesa BioSciences has won the 2026 Georgia Life Sciences Golden Helix Award for Deal of the Year, recognising its oversubscribed $75 million Series B financing round. The funding, led by Forbion with participation from Sanofi, Medicxi, Pitango, and Atlantic Partners, will advance the clinical-stage pharmaceutical company's lead therapy, vapendavir. Vapendavir is an investigational oral treatment for chronic lung diseases including COPD and asthma. The drug is currently being evaluated in the Phase 2b CARDINAL trial, which will enrol 900 COPD patients across the US and UK. The Georgia Research Alliance Venture Fund was an early investor in Altesa. The company's scientific founders previously helped develop molnupiravir, one of the earliest COVID-19 treatments.

Business Wire
Aug 13th, 2026
Epicrispr Biotechnologies Closes $90 Million Oversubscribed Series C Financing to Advance First-in-Class Epigenetic Therapy Toward Pivotal Studies in FSHD

Epicrispr Biotechnologies Closes $90 Million Series C Financing to Advance First-in-Class Epigenetic Therapy Toward Pivotal Studies in FSHD

Morningstar
Aug 12th, 2026
InduPro raises $77M Series B, doses first patient in Phase 1 trial of bispecific ADC for lung cancer

InduPro has closed a $77 million Series B financing round and dosed its first patient in a Phase 1 study of IDP-001, its lead oncology programme. The biotechnology company is developing IDP-001, a bispecific antibody-drug conjugate targeting EGFR and a novel tumour-associated proximity antigen, for treating advanced squamous non-small cell lung cancer and other solid tumours. The Column Group led the financing round, with participation from Vida Ventures, MRL Ventures Fund, Emerson Collective, Euclidean Capital, Solasta Ventures, Sanofi, and Eli Lilly and Company. Proceeds will support Phase 1 clinical development and early proof-of-concept data generation for IDP-001, whilst advancing InduPro's broader preclinical pipeline. InduPro uses a proximity-guided platform to map protein spatial relationships on cell surfaces for discovering selective co-target pairs.

FinancialContent
Jul 24th, 2026
Scribe Therapeutics prices upsized $129M IPO at top of range

Scribe Therapeutics, a clinical-stage biotechnology company developing in vivo CRISPR technologies, has priced its upsized initial public offering at $15.00 per share, the high end of its range. The company is offering 8,580,000 shares, expecting to raise $128.7 million in gross proceeds before fees and expenses. Scribe has also granted underwriters a 30-day option to purchase up to 1,287,000 additional shares. The shares are expected to begin trading on the Nasdaq Global Market on 24 July 2026 under the ticker symbol "SCTX", with the offering closing on 27 July 2026. Additionally, Scribe has agreed to sell 500,000 shares at the same price to Sanofi in a concurrent private placement. Leerink Partners, Goldman Sachs, Guggenheim Securities, and Wells Fargo Securities are serving as joint book-running managers.